Sermorelin
Sermorelin
ermorelin Acetate (GHRH 1-29) is a high-purity (≥99%) synthetic peptide for research. Verified CAS 86168-78-7.
The primary compliant GHRH agonist for investigating pituitary pulsatility, sleep architecture, and neuroendocrine function.
USA Cold-Chain Stored. Research Use Only (RUO).
Prodcut Specification
- Product Name : Sermorelin Acetate (Research Grade)
- CAS Number : 86168-78-7
- Synonyms / Common Names : Sermorelin acetate hydrate 114466-38-5 AKOS040744848
- Molecular Formula : C151H252N44O45S
- Molecular Weight : 3436.0 g/mol
-
Peptide Type: GHRH Receptor Agonist (Research Peptide)
- Target Receptor : GHRH Receptor (GHRHR)
- Purity : ≥99% (HPLC Verified)
- Form : Lyophilized White Powder
- Solubility : Soluble in Solution
- Endotoxin Level : Less than 1.0 EU/mg
Disclaimer : For Research Use Only (RUO). Not for human use.
Chemical Identity & “Survivor” Status
Sermorelin (GRF 1-29) is a synthetic polypeptide comprising the first 29 amino acids of endogenous human GHRH. Unlike newer synthetic peptides that have faced regulatory bans, it possesses a unique “Safe Harbor” status in the USA.
Structural Efficiency : It contains the full biological activity of GHRH within the N-terminal 29-amino acid sequence, making it highly specific to the GHRH receptor.
Regulatory note: Because it is the active ingredient of the formerly marketed product Geref (not withdrawn for safety reasons), Sermorelin remains available for compliant laboratory research on the somatotropic axis under applicable compounding and research-use rules.
GHRH Receptor Signaling: Sermorelin is investigated for its interaction with GHRH receptors and associated pulsatile endocrine signaling pathways in experimental research models.
Chemical structure of Sermorelin Acetate (GRF 1-29)
Verified 2D chemical structure of Sermorelin Acetate (GHRH 1-29) peptide (CAS 86168-78-7) showing the biologically active N-terminal fragment for pituitary research.
This synthetic 29-amino-acid peptide is an acetate salt form of a GHRH-related sequence, prepared for stability and solubility in laboratory research assays.
Comparative Research Overview: Sermorelin and Related Peptide Signaling Pathways
It is distinct because it works with the body’s natural feedback loops, specifically the inhibitory control of somatostatin.
Research Context & Clinical Insights (2025-2026)
| Parameter | Sermorelin (GHRH) |
Synthetic Research Compound |
GLP/GIP/GLC-Rt / GLP/GIP-Tz (Incretins) |
|---|---|---|---|
| Mechanism | Stimulates Endogenous GH | Replaces Natural GH | GLP-1 / GIP Agonism |
| Release Pattern | Pulsatile (Natural Spikes) | “Square Wave” (Continuous) | Constant Exposure |
| Feedback Loop | Preserved (Safe) | Bypassed (Suppressive) | N/A (Metabolic Focus) |
| Primary Research | Sleep Architecture (SWS) Research Models | Height / Growth Failure | Body-Weight & Glucose Pathway Research |
| Safety Profile | Self-Limiting (No Overdose) | Risk of Acromegaly/Edema | GI Distress |
Sleep Architecture (Deep Sleep)
In published research models, it is examined as a neurotransmitter-linked compound in Slow-Wave Sleep (SWS) assays and age-related sleep marker studies under controlled laboratory conditions.
Body Composition & Visceral Fat : By restoring GH pulsatility, Sermorelin reactivates lipolytic machinery in visceral fat depots. Studies in aging models showed increases in lean body mass (+1.4 kg in men) and improvements in skin thickness (collagen density)
The “Stacking” Shift : With Ipamorelin now placed in FDA Category 2 (restricted), researchers are shifting focus to Sermorelin Monotherapy. It remains the primary legal tool for stimulating the somatotropic axis in the USA.
Why Researchers Source Sermorelin from Profound Aminos
The “Grey Market” Antidote: While many vendors sell undefined “research chemicals,” our Sermorelin is strictly tested to confirm it is NOT a salt-heavy synthesis byproduct. We ensure <1.0 EU/mg endotoxin levels for safe cellular assays.
USA-Based Cold-Chain: Peptides are fragile. We store our inventory at -20°C in the USA to prevent degradation of the amino acid sequence before it reaches your lab.
Verified Sequence: COA confirms the 1-29 fragment identity, ensuring you are researching the specific biologically active motif.
Regulatory & Compliance Statement
Classification : Research Use Only (RUO) Peptide.
Compliance: Sermorelin acetate is listed as a bulk substance for 503A compounding under the FD&C Act. It is the API associated with the formerly marketed product Geref.
Usage: Strictly for Laboratory Research Use Only. Not for human or animal use, diagnostic, or clinical procedures.